Clinical Trial Update: Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and effectiveness of switching from Humira to Imraldi in inflammatory bowel diseases in Flanders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• Humira (adalimumab)
• Imraldi (adalimumab)

Snippet

Sponsor: Pieter Dewint, MD PhD | Conditions: Inflammatory Bowel Diseases | Phase 4 | Status: COMPLETED